|
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
| RELATED ARTICLES | | |
|
Merck and Moderna report that a personalized mRNA vaccine helped prevent skin cancer from returning in high-risk patients. Observers greeted the news with enthusiasm but noted that full data from the ongoing late-stage study has yet to be released.
|
|